- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsing-remitting multiple sclerosis (RRMS)
- Meeting Date: September 2020
- Public Summary Document (PSD) September 2020 PBAC Meeting - (PDF 1203KB)
- Public Summary Document (PSD) September 2020 PBAC Meeting - (Word 76KB)
Ozanimod – September 2020
Ozanimod: Capsule 230 micrograms, Capsule 460 micrograms, Capsule 920 micrograms; Zeposia®
Last updated
24 December 2020